Recently, IBR854 Cell Injection of iMBioRay (Hangzhou) Biomedical Co., Ltd. (iMBioRay) obtained the permission of the NMPA for clinical trials. IBR854 Injection is a universal off-the-shelf CAR-raNK cell product derived from allogeneic peripheral blood. The indication is the treatment of patients with unresectable locally advanced or metastatic solid tumors who currently have no or cannot tolerate standard treatment. It is the first non-gene-modified CAR-raNK cell therapy for solid tumors in China, and the world's first FIC (First in class) products. Shanghai Medicilon Inc. (Medicilon), as a partner of IBR854 Cell Injection, provides efficient, high-quality and comprehensive preclinical research services (including pharmacokinetic studies and safety evaluation) in compliance with GLP regulations. The IBR854 Cell Injection is successfully approved at the end. Medicilon cell immunotherapy drug service platform Enabling the sustainable development of global cellula...
Integrated Drug Discovery Services- Chemistry, Biology & Preclinical Services